Kintara Therapeutics Inc [NASDAQ: KTRA] gained 17.34% or 0.02 points to close at $0.14 with a heavy trading volume of 24171954 shares. The company report on December 7, 2023 at 9:00 AM that Kintara Therapeutics Announces Review of Strategic Alternatives.
– Ladenburg Thalmann Hired as Financial advisor -.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value.
The daily chart for KTRA points out that the company has recorded -96.55% loss over the past six months.
If we look at the average trading volume of 6.01M shares, KTRA reached to a volume of 24171954 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Kintara Therapeutics Inc [KTRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KTRA shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KTRA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Trading performance analysis for KTRA stock
Kintara Therapeutics Inc [KTRA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.67. With this latest performance, KTRA shares dropped by -14.62% in over the last four-week period, additionally sinking by -96.55% over the last 6 months – not to mention a drop of -97.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KTRA stock in for the last two-week period is set at 37.88, with the RSI for the last a single of trading hit 51.31, and the three-weeks RSI is set at 31.65 for Kintara Therapeutics Inc [KTRA]. The present Moving Average for the last 50 days of trading for this stock 0.2086, while it was recorded at 0.1303 for the last single week of trading, and 2.6712 for the last 200 days.
Kintara Therapeutics Inc [KTRA]: A deeper dive into fundamental analysis
Kintara Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.23 and a Current Ratio set at 0.23.
Kintara Therapeutics Inc [KTRA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Kintara Therapeutics Inc posted -3.5/share EPS, while the average EPS was predicted by analysts to be reported at 0/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for KTRA.
An analysis of Institutional ownership at Kintara Therapeutics Inc [KTRA]
The top three institutional holders of KTRA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in KTRA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in KTRA stock with ownership which is approximately 5.8325%.
